Abstract Library

#4282 A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumours and carcinomas

Introduction: Neuroendocrine neoplasms (NENs) consist of neuroendocrine tumours and neuroendocrine carcinomas, which are rare malignancies found in various anatomical sites, including the gastrointestinal tract, pancreatic islets, lungs, and adrenal glands. Poorly differentiated NECs are classified as high-grade carcinomas that bear resemblance to small-cell lung cancer; however, these patients experience a high risk of relapse and demonstrate a limited response to additional systemic therapies. Adrenocortical carcinoma (ACC) is another rare cancer and currently, no targeted therapies have demonstrated significant effectiveness for this condition. Preclinical investigations have indicated that Delta-like non-canonical notch ligand 1 (DLK1) is expressed in various neuroendocrine neoplasms, including ACC, SCLC, neuroblastoma, pheochromocytoma, and paraganglioma.

Conference:

Presenting Author: Del Rivero J

Authors: Del Rivero J, Glod J, Magee T, Cooper K, Rivero A,

Keywords: NEN, NEC, NET, ACC, ADC, ADCT-701,

#3953 Olaparib use in a patient diagnosed with BRCA2 mutated adrenocortical carcinoma: A case report

Introduction: Adrenocortical carcinoma (ACC) is a highly lethal endocrine malignancy with an estimated annual incidence of 1.5–2 cases per million. Only a small percentage of ACC cases are associated with hereditary cancer syndromes while, equally only a few cases, have been reported with BRCA mutation. Targeted therapy of ACC with germline mutations is an area of research which renders the treatment approach challenging.

Conference:

Presenting Author:

Authors: Kontana E, Tikas I, Boudina M, Chrysoulidou A, Andreadou A,

Keywords: adrenocortical carcinoma, brca2 mutation, olaparib,

#3939 Machine learning-based identification of disulfidptosis-associated signature for improving outcomes and immunotherapy responses in patients with adrenocortical carcinoma

Introduction: Disulfidptosis, a newly discovered type of cell death, has been found to be closely associated with the onset and progression of tumors. Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy originating from the adrenal cortex.

Conference:

Presenting Author:

Authors: Liu S,

Keywords: disulfidptosis, machine learning, immunotherapy, adrenocortical carcinoma, prognosis, drugs,

#3936 Dissecting the intra- and inter-tumor heterogeneity of adrenocortical carcinoma by single-cell multi-omics analyses

Introduction: Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy originating in the adrenal cortex, characterized by significant intra- and inter-tumor heterogeneity.

Conference:

Presenting Author:

Authors: Liu S, Chong C,

Keywords: Adrenocortical carcinoma, immune therapy, tumor heterogeneity,

#3918 Efficiency of GemCap + mitotane in platinum and mitotane resistant adrenocortical carcinoma

Introduction: Gemcitabine, metronomic capecitabine and mitotane (M) combination (GemCap + M) is the most investigated and widely used regimen in 2nd and subsequent lines therapy of advanced adrenocortical cancer (ACC). In the largest retrospective study (N=145) only 28% of patients (pts) reached therapeutic concentration of mitotane (M), which translated into a significant improvement in the median progression free survival (PFS).

Conference:

Presenting Author: Zhulikov Y

Authors: Zhulikov Y, Kovalenko E, Bokhyan V, Evdokimova E, Khoroshilov M,

Keywords: adrenocortical cancer, gemcitabine, capecitabine, GemCap, mitotane,